This is the limited version of the Alkermes company profile: Join LinkedIn or Sign In to see more information.
Fully integrated biotechnology company that develops innovative medicines and drug-delivery technology designed to yield better therapeutic outcomes for patients. The company has two commercial products: RISPERDAL® CONSTA® approved for treatment of schizophrenia and bipolar I disorder, and marketed worldwide through a division of Johnson & Johnson, and VIVITROL® approved for the treatment of alcohol dependence and marketed by Alkermes.
Your Connections to Alkermes
Popular Profiles at Alkermes
New Hires and Recent Promotions at Alkermes
-
Claire Vasios, Vice President, Intellectual Property
was Director, Intellectual Property - 6 months ago
-
Eva Stroynowski, Senior Corporate Communications Specialist
was Senior Corporate Communications Associate - last month
Last edited by Administrative Assistant at Alkermes
88 Sidney Street
Cambridge, MA
02139-4136
United States
Phone: 617-494-0171
Fax: 617-494-9263
| Headquarters | Greater Boston Area |
|---|
| Industry | Biotechnology |
|---|
| Type | Public Company |
|---|
| Status | Operating |
|---|
| Company Size |
580 employees
|
|---|
| 2007 Revenue |
$240
mil
(44%)
|
|---|
| Founded | 1987 |
|---|
| Website | http://www.alkermes.com |
|---|
Estimated based on LinkedIn Data
Career path for Alkermes employees
News about Alkermes
-
From: | November 06, 2009
-
From: | November 12, 2009
-
From: | November 06, 2009
In partnership with 
Send feedback on BusinessWeek/CapIQ content to linkedinissues@capitaliq.com. Copyright © 2009 Capital IQ.
This LinkedIn Company Profile was created by LinkedIn and is about Alkermes. This page is not endorsed by or affiliated with Alkermes. For questions regarding LinkedIn Company Profiles, contact us.
Interactive Data Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions
